Clinical cancer research : an official journal of the American Association for Cancer Research · 2018
Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tallón de Lara Paulino, Cecconi Virginia, Hiltbrunner Stefanie, Yagita Hideo, Friess Martina, Bode Beata, Opitz Isabelle, Vrugt Bart, Weder Walter, Stolzmann Paul, Felley-Bosco Emanuela, Stahel Rolf A, Tischler Verena, Britschgi Christian, Soldini Davide, van den Broek Maries, Curioni-Fontecedro Alessandra
Аннотация
PURPOSE: Combination of immune checkpoint inhibitors with chemotherapy is under investigation for cancer treatment.
EXPERIMENTAL DESIGN: We studied the rationale of such a combination for treating mesothelioma, a disease with limited treatment options.
RESULTS: The combination of gemcitabine and immune checkpoint inhibitors outperformed immunotherapy alone with regard to tumor control and survival in a preclinical mesothelioma model; however, the addition of dexamethasone to gemcitabine and immune checkpoint inhibitors nullified the synergistic clinical response. Furthermore, treatment with gemcitabine plus anti-PD-1 resulted in an objective clinical response in two patients with mesothelioma, who were resistant to gemcitabine or anti-PD-1 as monotherapy.
CONCLUSIONS: Thus, treatment of mesothelioma with a combination of gemcitabine with immune checkpoint inhibitors is feasible and results in synergistic clinical response compared with single treatment in the absence of steroids.
EXPERIMENTAL DESIGN: We studied the rationale of such a combination for treating mesothelioma, a disease with limited treatment options.
RESULTS: The combination of gemcitabine and immune checkpoint inhibitors outperformed immunotherapy alone with regard to tumor control and survival in a preclinical mesothelioma model; however, the addition of dexamethasone to gemcitabine and immune checkpoint inhibitors nullified the synergistic clinical response. Furthermore, treatment with gemcitabine plus anti-PD-1 resulted in an objective clinical response in two patients with mesothelioma, who were resistant to gemcitabine or anti-PD-1 as monotherapy.
CONCLUSIONS: Thus, treatment of mesothelioma with a combination of gemcitabine with immune checkpoint inhibitors is feasible and results in synergistic clinical response compared with single treatment in the absence of steroids.
Предметные рубрики MeSH
AnimalsAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenBiomarkers, TumorBiopsyCell Line, TumorDeoxycytidineDisease Models, AnimalDrug Resistance, NeoplasmDrug SynergismGene ExpressionHumansImmunomodulationLung NeoplasmsMesotheliomaMesothelioma, MalignantMicePositron Emission Tomography Computed TomographyPrognosisTreatment OutcomeXenograft Model Antitumor AssaysGemcitabine